Spinal Muscular Atrophy

October 9th 2024

The higher dose led to a more rapid decline in an important marker of neurodegeneration, according to a Biogen news release announcing the results.

September 20th 2024

Study of 29 children treated with Zolgensma (onasemnogene abeparvovec) shows mixed results.

September 13th 2024

U.S. providers surveyed said that getting insurance approval is time-consuming and can delay treatment for newborns with spinal muscular atrophy.

September 11th 2024

Data from the DEVOTE study suggest that 50-milligram doses are safe and effective.